Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline

After human papillomavirus (HPV) vaccine guidelines published by Korean Society of Gynecologic Oncology (KSGO) in 2011, new studies have been published, leading to additional data regarding efficacy, safety, number of vaccination rounds, and ideal age of vaccine administration. We searched and revie...

Descripción completa

Detalles Bibliográficos
Autores principales: Min, Kyung-Jin, Kwon, Sang-Hoon, Kim, Sunghoon, Kim, Hyun Jung, Seong, Seok Ju, Song, Yong Jung, Shin, Jin Woo, Lee, Keun-Ho, Lim, Myong Cheol, Chung, Hyun Hoon, Ju, Woong, Hong, Jin Hwa, Lee, Jeong-Won, Kim, Jae-Weon, Bae, Duk-Soo, Lee, Jae-Kwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823361/
https://www.ncbi.nlm.nih.gov/pubmed/27029751
http://dx.doi.org/10.3802/jgo.2016.27.e30
Descripción
Sumario:After human papillomavirus (HPV) vaccine guidelines published by Korean Society of Gynecologic Oncology (KSGO) in 2011, new studies have been published, leading to additional data regarding efficacy, safety, number of vaccination rounds, and ideal age of vaccine administration. We searched and reviewed the literatures focused on the efficacy of 2-dose schedule vaccination, the efficacy of 3-dose schedule vaccination in middle-aged women, the ideal age of 3-dose schedule vaccination, the safety of HPV preventive vaccine, and the ability of cross-protection of each HPV preventive vaccine. The KSGO has revised the previous guideline based on the results of the above studies.

Ejemplares similares